Integrated genomic analyses of de novo pathways underlying atypical meningiomas

Citations Over TimeTop 1% of 2017 papers

Abstract

Meningiomas are mostly benign brain tumours, with a potential for becoming atypical or malignant. On the basis of comprehensive genomic, transcriptomic and epigenomic analyses, we compared benign meningiomas to atypical ones. Here, we show that the majority of primary (de novo) atypical meningiomas display loss of NF2, which co-occurs either with genomic instability or recurrent SMARCB1 mutations. These tumours harbour increased H3K27me3 signal and a hypermethylated phenotype, mainly occupying the polycomb repressive complex 2 (PRC2) binding sites in human embryonic stem cells, thereby phenocopying a more primitive cellular state. Consistent with this observation, atypical meningiomas exhibit upregulation of EZH2, the catalytic subunit of the PRC2 complex, as well as the E2F2 and FOXM1 transcriptional networks. Importantly, these primary atypical meningiomas do not harbour TERT promoter mutations, which have been reported in atypical tumours that progressed from benign ones. Our results establish the genomic landscape of primary atypical meningiomas and potential therapeutic targets.

Related Papers

• → The noncanonical role of EZH2 in cancer(2021)92 cited
• → Targeting EZH2 as cancer therapy(2021)54 cited
• → Targeting EZH2 for Cancer Therapy: Progress and Perspective(2015)64 cited
• → Enhancer of zeste homolog 2: A potential target for tumor therapy(2011)39 cited
• → Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities(2022)8 cited